D Nyholm

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Clin Pharmacokinet 45:109-36. 2006
  2. ncbi request reprint The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Parkinsonism Relat Disord 13:S13-7. 2007
  3. ncbi request reprint Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Neurology 65:1506-7. 2005
  4. ncbi request reprint Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Neurology 64:216-23. 2005
  5. doi request reprint Irregular gastrointestinal drug absorption in Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Expert Opin Drug Metab Toxicol 4:193-203. 2008
  6. ncbi request reprint Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Mov Disord 19:446-51. 2004
  7. doi request reprint Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Clin Neuropharmacol 31:63-73. 2008
  8. ncbi request reprint Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University, Sweden
    Clin Neuropharmacol 26:156-63. 2003
  9. doi request reprint Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Acta Neurol Scand 119:345-8. 2009
  10. ncbi request reprint Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185, Uppsala, Sweden
    Expert Rev Neurother 6:1403-11. 2006

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Clin Pharmacokinet 45:109-36. 2006
    ..CDS can be approached by optimising the use of dopaminergic drugs based on pharmacokinetic data...
  2. ncbi request reprint The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Parkinsonism Relat Disord 13:S13-7. 2007
    ..Treatment strategies that provide a continuous flow of dopamine and can thus mimic normal physiological dopamine stimulation have potential to improve motor control for patients with advanced PD...
  3. ncbi request reprint Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Neurology 65:1506-7. 2005
  4. ncbi request reprint Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Neurology 64:216-23. 2005
    ..To compare daytime intraduodenal levodopa/carbidopa infusion as monotherapy with individually optimized conventional combination therapies in patients with advanced Parkinson disease (PD) for motor fluctuations and quality of life (QoL)...
  5. doi request reprint Irregular gastrointestinal drug absorption in Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Expert Opin Drug Metab Toxicol 4:193-203. 2008
    ..Levodopa is only absorbed in the small intestine, where transit time is approximately 3 h and the plasma elimination half-life is short. Therefore, gastric emptying is a major determining factor for onset of symptom relief...
  6. ncbi request reprint Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Mov Disord 19:446-51. 2004
    ..Electronic diaries can be used for self-assessment of PD symptoms. The real-time feature provides fast access to clean data with knowledge of true compliance...
  7. doi request reprint Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Clin Neuropharmacol 31:63-73. 2008
    ..This is a retrospective analysis of the long-term clinical experience with this agent...
  8. ncbi request reprint Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University, Sweden
    Clin Neuropharmacol 26:156-63. 2003
    ..Continuous intraduodenal delivery of a new carbidopa/levodopa formulation offers a means for markedly improved control of motor fluctuations in late stages of PD...
  9. doi request reprint Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Acta Neurol Scand 119:345-8. 2009
    ..No comparative trials of these two alternatives were performed...
  10. ncbi request reprint Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185, Uppsala, Sweden
    Expert Rev Neurother 6:1403-11. 2006
    ..The infusion provides smooth plasma levodopa levels, more continuous dopaminergic stimulation and effective treatment of motor complications...
  11. doi request reprint Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion
    D Isacson
    Department of Pharmacy, Pharmacoepidemiology and Pharmacoeconomics, Uppsala University, Sweden
    Acta Neurol Scand 118:379-86. 2008
    ..To assess fluctuations in quality of life (QoL) and motor performance in patients with advanced Parkinson disease (PD) treated with continuous daytime duodenal levodopa/carbidopa infusion or conventional therapy...
  12. ncbi request reprint Duodenal levodopa infusion in Parkinson's disease--long-term experience
    D Nilsson
    Department of Neuroscience, Neurology, Uppsala University, Sweden
    Acta Neurol Scand 104:343-8. 2001
    ..Short-term results have already been published and a follow-up showing continued positive effect after 4-7 years of continuous duodenal infusion is presented...
  13. doi request reprint Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden
    Eur J Neurol 19:1079-85. 2012
    ..There is compelling evidence for short-term use of this treatment; however, long-term data are scarce...
  14. doi request reprint Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University, Sweden
    Acta Neurol Scand 127:124-32. 2013
    ..An oral dispersible microtablet formulation of levodopa/carbidopa 5/1.25 mg (LC-5) was developed for individualized repeated dosing. The aim was to compare pharmacokinetic profiles of LC-5 and levodopa/carbidopa/entacapone (LCE)...
  15. doi request reprint Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women
    D Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden
    Eur J Neurol 17:260-6. 2010
    ..The aims were to investigate the use of levodopa in a nationwide Swedish survey and to study the characteristics of low-dose and high-dose patients with Parkinson's disease (PD) in a university hospital...
  16. doi request reprint Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial
    D Nyholm
    Department of Neuroscience, Uppsala Department of Pharmacy, Uppsala University, Uppsala, Sweden
    Eur J Neurol 19:820-6. 2012
    ....
  17. ncbi request reprint Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease
    J Westin
    Department of Medical Sciences, Biomedical Informatics and Engineering, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Parkinsonism Relat Disord 12:509-13. 2006
    ..Using data from one study, a prediction model was designed and was then evaluated using the other study's data. Correlations were found indicating that patients with more severe symptoms at baseline were most improved after infusion...
  18. ncbi request reprint [Changing neurology--from diagnostic to therapeutic discipline]
    Anja Smits
    Neurologiska kliniken, Akademiska sjukhuset, Uppsala
    Lakartidningen 105:2413-6. 2008
  19. ncbi request reprint Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations
    Dag Nyholm
    Department of Neuroscience, Uppsala University, Sweden
    Clin Neuropharmacol 25:89-96. 2002
    ..Variation in levodopa concentration is the determining factor for motor fluctuations also in patients on clinically optimized combinations with dopamine agonists and enzyme inhibitors...
  20. ncbi request reprint Levodopa infusion therapy in Parkinson disease: state of the art in 2004
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, Sweden
    Clin Neuropharmacol 27:245-56. 2004
    ..The results acquired so far suggest that levodopa infusion is a safe and efficacious therapy. Recent drug delivery development and long-term studies have shown that infusion is a clinically feasible alternative to treat advanced PD...
  21. doi request reprint Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease
    Rickard Nyman
    Department of Diagnostic Radiology, Uppsala University Hospital, Uppsala, Sweden
    J Vasc Interv Radiol 20:500-5. 2009
    ....
  22. doi request reprint Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease
    Dag Nyholm
    Department of Neuroscience, Neurology, and daggerDepartment of Pharmacy, BMC, Uppsala University, Uppsala, Sweden
    Clin Neuropharmacol 33:181-5. 2010
    ..The purpose of this study was to compare daytime and nighttime plasma pharmacokinetics (PK) of levodopa in patients with Parkinson disease...
  23. ncbi request reprint An automatic dose dispenser for microtablets--a new concept for individual dosage of drugs in tablet form
    Susanne Bredenberg
    Department of Pharmacy, Uppsala University, SE 751 23, Uppsala, Sweden
    Int J Pharm 261:137-46. 2003
    ..It is concluded that the final version of the automatic dose dispenser concept will offer potential for improvement of drug administration for patients with PD or other diseases requiring individual dosage...
  24. ncbi request reprint New developments in levodopa therapy
    Peter A LeWitt
    Department of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, Michigan, USA
    Neurology 62:S9-16. 2004
    ..Evidence suggests that altering the delivery of levodopa to provide a more continuous supply of this drug to the brain may result in improved control of PD symptoms...